Blue Matter

Pharma Tech

Vivera Pharmaceuticals, Inc. | May 26, 2022

Vivera is pleased to announce the allowance of its third U.S. patent for ZICOH™, the Company's high-tech, electronic dose-controlled portfolio of drug delivery devices. The patent allowance from the U.S. Patent and Trademark Office secures ZICOH's rights as a smart dosing system with automated delivery, measurement, and management for oral format medications, including pills, capsules, and tablets. ZICOH is an electronic dose-controlled delivery device and technology...

Business Insights

Novartis Pharma AG | March 14, 2022

Sandoz, a Novartis division, announced that it has successfully acquired the UK-based medical and drug delivery device development company, Coalesce Product Development Limited. Through this deal, Sandoz has acquired the significant capabilities and assets of Coalesce, which will help it build on its existing portfolio of respiratory medicines and further improve patient access to these high-quality, complex therapies. “Respiratory and co...

Pharmacy Market

MEDISCA | June 18, 2021

MEDISCA has chosen Creatio's low-code platform for process management and CRM, the company said today. MEDISCA, a global leader in pharmaceutical compounding, chose Creatio to speed up processes, improve market share among current partners, and boost revenue per employee. MEDISCA assists pharmacists by supplying equipment, devices, and high-quality ingredients. MEDISCA has a good reputation in the pharmaceutical compounding business as an innovative and entrepreneurial company...

Business Insights

The Mid-Atlantic Technology, | March 03, 2022

The Mid-Atlantic Technology, Research & Innovation Center announced it will establish the Center of Excellence for process design, defining a new standardized process development framework to streamline chemical manufacturing processes from laboratory bench through to commercial production. The initial projects will develop continuous processes for critical materials for the pharmaceutical industry currently substantially produced overseas. These new capabilities will be established as a res...